drugset / Trial / NCT03774680

Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer

NCT03774680

Phase 1 Unknown 30 enrolled Al-Azhar University
RandomizedParallel-groupSingle-blindTreatment

Summary

Due to the great toxicity of chemotherapeutic drugs to both the healthy and cancerous area, the efficient targeting could be of great benefit for a patient with advanced or metastatic tumors. Colorectal cells carry somatostatin receptors which make them a promising target for antitumor therapy since this would reduce side effects and increase drug delivery efficacy to the target site.

Timeline

Start
2020-02-01
Primary completion
2020-02-01
Completion
2021-01-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cetuximab Monoclonal antibody Oral

Indications